🍽️ oxantel pamoate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antiparasitic Activity: Oxantel pamoate works by paralyzing and killing adult worms (nematodes) in the intestines, specifically targeting infections caused by roundworms (Ascaris lumbricoides).

  2. Indications: It is commonly used for the treatment of ascariasis, which is a parasitic infection caused by the roundworm Ascaris lumbricoides. Ascariasis is one of the most common human parasitic infections worldwide, particularly in areas with poor sanitation and hygiene.

  3. Mechanism of Action: Oxantel pamoate exerts its anthelmintic effect by selectively inhibiting the enzyme fumarate reductase in the parasites, leading to paralysis and subsequent expulsion of the worms from the gastrointestinal tract.

  4. Dosage and Administration: Oxantel pamoate is usually administered orally as a single dose or in divided doses, depending on the severity of the infection and the patient's age. The dosage regimen may vary based on factors such as body weight and the specific parasite being targeted.

  5. Efficacy: Oxantel pamoate is effective against adult roundworms but may not eliminate immature or migrating larvae. Therefore, additional treatments or combination therapy with other anthelmintic drugs may be necessary to achieve complete eradication of the infection.

  6. Safety Profile: Oxantel pamoate is generally well-tolerated when used at recommended doses. However, like all medications, it may cause side effects in some individuals. Common side effects may include gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea.

  7. Contraindications: Oxantel pamoate is contraindicated in individuals with known hypersensitivity or allergy to the drug or its components. It should also be used with caution in pregnant or breastfeeding women, as its safety profile in these populations has not been well-established.

  8. Adverse Reactions: Serious adverse reactions to oxantel pamoate are rare but may include allergic reactions (such as rash, itching, or swelling), severe abdominal pain, or signs of intestinal obstruction. If any adverse effects occur, medical attention should be sought promptly.

  9. Drug Interactions: Oxantel pamoate is not known to interact significantly with other medications. However, it's essential to inform healthcare providers about all medications, supplements, and herbal products being taken to prevent potential interactions.

  10. Follow-Up: After treatment with oxantel pamoate, follow-up stool examinations may be recommended to confirm the eradication of the parasitic infection and ensure treatment success.

  11. Preventive Measures: In addition to medication, preventive measures such as improved sanitation, personal hygiene practices (including handwashing), and the provision of clean drinking water are essential for the prevention and control of parasitic infections.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of oxantel pamoate,(prescription) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by oxantel pamoate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Clostridioides genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Thomasclavelia genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Phocaeicola genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Bilophila wadsworthia species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
[Ruminococcus] gnavus species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Phocaeicola vulgatus species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Streptococcus parasanguinis species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of oxantel pamoate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.2 0.2
ADHD 0.9 0.9
Age-Related Macular Degeneration and Glaucoma 0.2 -0.2
Allergic Rhinitis (Hay Fever) 1.2 1.2
Allergies 1.7 0.3 4.67
Allergy to milk products 1 0.4 1.5
Alopecia (Hair Loss) 0.2 0.2
Alzheimer's disease 1.7 1 0.7
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.4 0.6 -0.5
Ankylosing spondylitis 1.2 0.7 0.71
Anorexia Nervosa 0.2 0.4 -1
Antiphospholipid syndrome (APS) 0.7 0.2 2.5
Asthma 0.3 0.1 2
Atherosclerosis 0.4 0.3 0.33
Atrial fibrillation 0.4 0.8 -1
Autism 3.3 1.6 1.06
Barrett esophagus cancer 0.3 0.1 2
benign prostatic hyperplasia 0.3 0.3
Biofilm 1.5 1.5
Bipolar Disorder 0.8 0.8
Brain Trauma 0.2 0.1 1
Cancer (General) 0.8 -0.8
Carcinoma 1.1 0.4 1.75
Celiac Disease 1.1 0.5 1.2
Cerebral Palsy 0.4 0.1 3
Chronic Fatigue Syndrome 2.5 1.3 0.92
Chronic Kidney Disease 0.9 0.2 3.5
Chronic Lyme 0.1 -0.1
Chronic Obstructive Pulmonary Disease (COPD) 0.8 0.8
Chronic Urticaria (Hives) 1.3 0.1 12
Coagulation / Micro clot triggering bacteria 1.1 0.1 10
Colorectal Cancer 2.4 0.2 11
Constipation 0.7 0.7
Coronary artery disease 0.5 0.5
COVID-19 3.4 2.1 0.62
Crohn's Disease 3.5 0.8 3.38
cystic fibrosis 0.9 0.1 8
deep vein thrombosis 0.9 0.1 8
Depression 2.5 2 0.25
Dermatomyositis 0.1 0.1
Eczema 0.6 0.9 -0.5
Endometriosis 1.3 1.3
Eosinophilic Esophagitis 0.3 0.3
Epilepsy 1 0.6 0.67
Fibromyalgia 1.2 0.9 0.33
Functional constipation / chronic idiopathic constipation 1.8 0.5 2.6
gallstone disease (gsd) 0.7 0.3 1.33
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.6 0.1 5
Generalized anxiety disorder 1.5 0.4 2.75
giant cell arteritis 0.3 -0.3
Glioblastoma 0.1 -0.1
Graves' disease 0.4 0.2 1
Halitosis 0.4 0.1 3
Hashimoto's thyroiditis 0.1 0.4 -3
Hidradenitis Suppurativa 0.6 0.6
High Histamine/low DAO 1.4 1.4
hypercholesterolemia (High Cholesterol) 0.3 0.3
hyperglycemia 0.3 0.3 0
Hyperlipidemia (High Blood Fats) 0.2 0.2 0
hypersomnia 0.2 -0.2
hypertension (High Blood Pressure 0.9 0.6 0.5
Hypoxia 0.3 0.3
IgA nephropathy (IgAN) 1.1 -1.1
Inflammatory Bowel Disease 2.6 0.8 2.25
Insomnia 0.2 0.1 1
Intelligence 0.8 0.8
Intracranial aneurysms 0.3 0.2 0.5
Irritable Bowel Syndrome 1.3 1.1 0.18
Liver Cirrhosis 1.5 0.8 0.88
Long COVID 2.3 1.3 0.77
Lung Cancer 0.3 0.3
Mast Cell Issues / mastitis 0.4 0.4
ME/CFS with IBS 0.5 0.1 4
ME/CFS without IBS 0.9 0.1 8
Metabolic Syndrome 3 2 0.5
Mood Disorders 3.5 2 0.75
multiple chemical sensitivity [MCS] 0.5 0.5
Multiple Sclerosis 1.2 1.3 -0.08
Multiple system atrophy (MSA) 0 0
neuropathic pain 0.1 -0.1
Neuropathy (all types) 0.1 0.3 -2
neuropsychiatric disorders (PANDAS, PANS) 0.6 0.6
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.9 0.1 8
Obesity 2 1.3 0.54
obsessive-compulsive disorder 2.8 0.5 4.6
Osteoarthritis 1.6 1.6
Osteoporosis 0.7 0.1 6
pancreatic cancer 0.1 0.1
Parkinson's Disease 1.3 0.7 0.86
Polycystic ovary syndrome 1.2 0.3 3
Postural orthostatic tachycardia syndrome 0.3 0.3
Premenstrual dysphoric disorder 0.2 0.2 0
primary biliary cholangitis 0.7 -0.7
Psoriasis 1.4 0.3 3.67
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.3 0.9 1.56
Rosacea 0.3 -0.3
Schizophrenia 2 0.3 5.67
scoliosis 0.2 -0.2
Sjögren syndrome 0.6 0.8 -0.33
Sleep Apnea 0.3 0.1 2
Slow gastric motility / Gastroparesis 0.7 0.7
Small Intestinal Bacterial Overgrowth (SIBO) 1 1
Stress / posttraumatic stress disorder 1.4 0.3 3.67
Systemic Lupus Erythematosus 1.6 1.6
Tic Disorder 0.3 0.2 0.5
Tourette syndrome 0.1 -0.1
Type 1 Diabetes 1 0.7 0.43
Type 2 Diabetes 3 2.4 0.25
Ulcerative colitis 1.5 1.6 -0.07
Unhealthy Ageing 2.7 2.7

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]